Daniel D. Von Hoff

70.3k total citations · 17 hit papers
821 papers, 44.9k citations indexed

About

Daniel D. Von Hoff is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Daniel D. Von Hoff has authored 821 papers receiving a total of 44.9k indexed citations (citations by other indexed papers that have themselves been cited), including 458 papers in Oncology, 377 papers in Molecular Biology and 177 papers in Cancer Research. Recurrent topics in Daniel D. Von Hoff's work include Pancreatic and Hepatic Oncology Research (170 papers), Cancer Treatment and Pharmacology (124 papers) and Cancer Genomics and Diagnostics (112 papers). Daniel D. Von Hoff is often cited by papers focused on Pancreatic and Hepatic Oncology Research (170 papers), Cancer Treatment and Pharmacology (124 papers) and Cancer Genomics and Diagnostics (112 papers). Daniel D. Von Hoff collaborates with scholars based in United States, Spain and United Kingdom. Daniel D. Von Hoff's co-authors include Haiyong Han, Howard A. Burris, Mace L. Rothenberg, Malcolm J. Moore, Russell K. Portenoy, M. Christine Cripps, Peter G. Tarassoff, Anna Maria Storniolo, John Sahl Andersen and F. Andrew Dorr and has published in prestigious journals such as Science, New England Journal of Medicine and Cell.

In The Last Decade

Daniel D. Von Hoff

805 papers receiving 43.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

1997 4.6k citations Howard A. Burris, Daniel D. Von Hoff et al. profile →
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure

1979 1.9k citations Daniel D. Von Hoff et al. profile →
Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma

2012 1.6k citations Daniel D. Von Hoff, Sunil R. Hingorani et al. profile →
Hypersensitivity reactions from taxol.

1990 951 citations Daniel D. Von Hoff et al. profile →
Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma

2009 833 citations Daniel D. Von Hoff, Patricia LoRusso et al. profile →
Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

2001 830 citations Manuel Hidalgo, Sabine Eckhardt et al. profile →
Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

2011 823 citations Daniel D. Von Hoff, Ramesh K. Ramanathan et al. profile →
Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449

2009 761 citations Charles M. Rudin, Patricia LoRusso et al. profile →
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

1997 745 citations Daniel D. Von Hoff et al. profile →
Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction.

1990 660 citations Daniel D. Von Hoff et al. profile →
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

2015 504 citations Daniel D. Von Hoff et al. profile →
Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer

2015 469 citations Caroline H. Diep, Galen Hostetter et al. Clinical Cancer Research profile →
Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type

2014 416 citations Daniel D. Von Hoff et al. profile →
Autophagy Is Critical for Pancreatic Tumor Growth and Progression in Tumors with p53 Alterations

2014 384 citations Annan Yang, N.V. Rajeshkumar et al. Cancer Discovery profile →
American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants

2008 378 citations Daniel D. Von Hoff et al. profile →
Perineural invasion and associated pain in pancreatic cancer

2011 349 citations Galen Hostetter, Daniel D. Von Hoff et al. profile →
Triptolide and Its Derivatives as Cancer Therapies

2019 233 citations Daniel D. Von Hoff, Haiyong Han et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel D. Von Hoff United States	91	23.6k	19.7k	8.3k	6.7k	4.1k	821	44.9k
Elisabeth G.E. de Vries Netherlands	102	24.1k 1.0×	14.3k 0.7×	6.4k 0.8×	7.4k 1.1×	6.1k 1.5×	1.0k	47.8k
Scott M. Lippman United States	89	12.8k 0.5×	13.5k 0.7×	7.9k 1.0×	10.6k 1.6×	2.6k 0.6×	528	37.2k
José Baselga United States	98	25.8k 1.1×	19.7k 1.0×	9.8k 1.2×	14.1k 2.1×	1.6k 0.4×	484	46.7k
Martin Gore United Kingdom	78	14.4k 0.6×	12.9k 0.7×	4.9k 0.6×	9.0k 1.3×	1.7k 0.4×	382	29.5k
Ka‐Fai To Hong Kong	100	8.9k 0.4×	13.5k 0.7×	7.6k 0.9×	6.2k 0.9×	4.1k 1.0×	566	34.7k
Eleftherios P. Diamandis Canada	103	9.7k 0.4×	17.2k 0.9×	6.2k 0.7×	5.8k 0.9×	1.5k 0.4×	940	44.5k
Lynn M. Matrisian United States	92	17.5k 0.7×	15.3k 0.8×	15.8k 1.9×	3.3k 0.5×	2.1k 0.5×	256	38.4k
Jan H.M. Schellens Netherlands	91	22.6k 1.0×	16.1k 0.8×	3.7k 0.4×	6.4k 0.9×	1.8k 0.4×	882	41.1k
José Baselga Spain	94	34.9k 1.5×	17.3k 0.9×	9.4k 1.1×	13.6k 2.0×	1.0k 0.3×	273	49.5k
Herbert M. Pinedo Netherlands	91	15.8k 0.7×	12.1k 0.6×	3.5k 0.4×	3.9k 0.6×	1.5k 0.4×	571	29.8k

Countries citing papers authored by Daniel D. Von Hoff

Since Specialization

Citations

This map shows the geographic impact of Daniel D. Von Hoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel D. Von Hoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel D. Von Hoff more than expected).

Fields of papers citing papers by Daniel D. Von Hoff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel D. Von Hoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel D. Von Hoff. The network helps show where Daniel D. Von Hoff may publish in the future.

Co-authorship network of co-authors of Daniel D. Von Hoff

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel D. Von Hoff. A scholar is included among the top collaborators of Daniel D. Von Hoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel D. Von Hoff. Daniel D. Von Hoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maity, Gargi, Arnab Ghosh, Inamul Haque, et al.. (2019). CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics. 18(4). 788–800. 30 indexed citations

Bendell, Johanna C., Valérie André, Alan L. Ho, et al.. (2018). Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma. Clinical Cancer Research. 24(9). 2082–2091. 59 indexed citations

Hoff, Daniel D. Von, Monica Mita, Ramesh K. Ramanathan, et al.. (2016). Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(13). 3157–3163. 215 indexed citations

Mine, Naoki, Sayaka Yamamoto, Donald Küfe, Daniel D. Von Hoff, & Takumi Kawabe. (2014). Activation of Nrf2 Pathways Correlates with Resistance of NSCLC Cell Lines to CBP501 In Vitro. Molecular Cancer Therapeutics. 13(9). 2215–2225. 10 indexed citations

Yang, Annan, N.V. Rajeshkumar, Xiaoxu Wang, et al.. (2014). Autophagy Is Critical for Pancreatic Tumor Growth and Progression in Tumors with p53 Alterations. Cancer Discovery. 4(8). 905–913. 384 indexed citations breakdown →

Saif, Muhammad Wasif, Charles Erlichman, Tomislav Dragovich, et al.. (2013). Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 71(5). 1345–1355. 25 indexed citations

Weekes, Colin D., Daniel D. Von Hoff, Alex A. Adjei, et al.. (2013). Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer. Clinical Cancer Research. 19(5). 1232–1243. 46 indexed citations

Spivak-Kroizman, Taly R., Galen Hostetter, Richard G. Posner, et al.. (2013). Hypoxia Triggers Hedgehog-Mediated Tumor–Stromal Interactions in Pancreatic Cancer. Cancer Research. 73(11). 3235–3247. 163 indexed citations

Siddiqui-Jain, Adam, Joshua Bliesath, Mayuko Omori, et al.. (2012). CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy. Molecular Cancer Therapeutics. 11(4). 994–1005. 86 indexed citations

10.

Graham, Richard, Bert L. Lum, Sravanthi Cheeti, et al.. (2011). Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding. Clinical Cancer Research. 17(8). 2512–2520. 97 indexed citations

11.

Mine, Naoki, Sayaka Yamamoto, Naoya Saito, et al.. (2011). CBP501-Calmodulin Binding Contributes to Sensitizing Tumor Cells to Cisplatin and Bleomycin. Molecular Cancer Therapeutics. 10(10). 1929–1938. 21 indexed citations

12.

Diep, Caroline H., Rubén M. Muñoz, Ashish Choudhary, Daniel D. Von Hoff, & Haiyong Han. (2011). Synergistic Effect between Erlotinib and MEK Inhibitors in KRAS Wild-Type Human Pancreatic Cancer Cells. Clinical Cancer Research. 17(9). 2744–2756. 66 indexed citations

13.

Galsky, Matthew D., Daniel D. Von Hoff, Marcus A. Neubauer, et al.. (2010). Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Investigational New Drugs. 30(2). 695–701. 52 indexed citations

14.

Warner, Steven L., Bret J. Stephens, Galen Hostetter, et al.. (2009). Validation of TPX2 as a Potential Therapeutic Target in Pancreatic Cancer Cells. Clinical Cancer Research. 15(21). 6519–6528. 86 indexed citations

15.

Balagurunathan, Yoganand, David L. Morse, Galen Hostetter, et al.. (2008). Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer. Molecular Cancer Therapeutics. 7(9). 3071–3080. 20 indexed citations

16.

Lorenzi, Philip L., William C. Reinhold, Martina Rudelius, et al.. (2007). Asparagine synthetase as a causal, predictive biomarker forL-asparaginase activity in ovarian cancer cells. Molecular Cancer Therapeutics. 5(11).

17.

Papadopoulos, Kyriakos P., Alain C. Mita, Alejandro D. Ricart, et al.. (2007). Pharmacokinetic findings from the phase I study of Quarfloxin (CX-3543): a protein-rDNA quadruplex inhibitor, in patients with advanced solid tumors.. Molecular Cancer Therapeutics. 6. 10 indexed citations

18.

Borad, Mitesh J., Robert Penny, Michael Bittner, et al.. (2006). Molecular profiling using immunohistochemistry (IHC) and DNA microarray (DMA) as a tool to determine potential therapeutic targets in patients who have progressed on multiple prior therapies. Clinical Cancer Research. 12. 4 indexed citations

19.

Marshall, Milton V., Martha H. Marshall, Donna Degen, et al.. (1993). In vitro cytotoxicity of hepsulfam against human tumor cell lines and primary human tumor colony forming units. Stem Cells. 11(1). 62–69. 9 indexed citations

20.

Clark, Gary M., et al.. (1991). Epidermal growth factor receptor amplification in head and neck cancer. 4(6). 375–381. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact